An open, single-arm, real-world study evaluating the efficacy and safety of allogeneic branch vascular replacement in the surgical treatment of pancreatic cancer with portal venous invasion

Prospective single-arm, single-center clinical study of branch allograft vascular replacement in the prevention of regional portal hypertension after pancreatic cancer surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049076

Enrollment

Unknown

Registered

2021-07-20

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Carcinoma

Interventions

Operation group:Radical resection of pancreatic cancer by allogeneic branch vascular replacement

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years old; 2. Preoperative imaging examinations suggest pancreatic malignancy; 3. Preoperative imaging examinations suggest that the portal vein-superior mesenteric vein-splenic vein junction is invaded, and the splenic vein needs to be reconstructed; 4. Preoperative evaluation of no major arterial and vascular invasion such as celiac trunk and superior mesenteric artery; 5. There is no metastasis to distant organs such as liver and lung in preoperative assessment; 6. There are no contraindications to surgery such as cardiopulmonary or other preoperative evaluation; 7. The expected survival period before surgery is more than 6 months; 8. Patients and their families agreed to the research protocol and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Intraoperative exploration has distant metastasis and give up radical operation; 2. Intraoperative exploration of the celiac trunk, superior mesenteric artery and other important arterial and vascular invasion and abandonment of radical surgery; 3. Intraoperative assessment of the splenic vein does not require reconstruction; 4. Postoperative pathology was non-pancreatic ductal adenocarcinoma.

Design outcomes

Primary

Measure	Time frame
biochemical criterion;overall survival time;disease free survival time;	—

Countries

China

Contacts

Public ContactHe Qiang/Lang Ren

Beijing Chaoyang Hospital

dr_langren@126.com+86 85231504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026